



Attorney Docket N . LeA 34 125C1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: NIEWOHNER, et al

Group Number:

Serial No.: 10/728180

Examiner:

Filed: 12 June 2002

For: Triazolotriazinones and the Use Thereof

CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, PO. Box 1450, Alexandria, VA 22313-1450.

Date: 14 January 2004

Monica M. McGovern
Monica McGovern

ASSISTANT COMMISSIONER FOR PATENTS
PO BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449. These references were cited in the International Search Report (Form PCT/ISA/210) for the corresponding International Application (PCT/US02/28912).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Pellegrino
Susan M. Pellegrino
Attorney for Applicant(s)
Bayer Corporation
400 Morgan Lane
West Haven, CT 06516

Reg. No. 48972

Telephone: (203) 812-6450

Date: 14 January 2004

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Serial No. 10/728180	Group Art Unit	Filing Date 04 December 2003	Atty. Docket No. Le A 34 125C1
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION		Applicant(s) NIEWÖHNER, et al					

U.S. PATENT DOCUMENTS										
*		DOCUMENT NO.				DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS										
		DOCUMENT NO.				DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION
										YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		
R1	Bhattacharya, "Synthesis of Certain N- and C-Alkyl Purine Analogs," <i>J. Heterocyclic Chem.</i> , <u>30</u> : 1341-1349 (1993)	
R2	Mitchell, "Synthesis of C-Nucleoside Isosteres of 9-(2-Hydroxyethoxymethyl) Guanine (Acyclovir), <i>J. Heterocyclic Chem.</i> , <u>21</u> : 697-699 (1984)	
R3	Rao, "Synthesis of Certain Acyclic Nucleoside Analogs of 1,2,4-Triazolo[3,4-f][1,2,4] Triazine and Pyrimido[5,4-d]Pyrimidine," <i>Nucleosides & Nucleotides</i> , <u>14</u> (7): 1601-1612 (1995)	
R4	Ramasamy, "Synthesis and Antitumor Activity of Certain 3-β-D-Ribofuranosyl-1,2,4-Triazolo[3,4-f]-1,2,4-Triazines Related to Formycin Prepared Via Ring Closure of a 1,2,4-Triazine Precursor," <i>J. Med. Chem.</i> , <u>29</u> : 2231-2235 (1986)	
R5	Beavo, "Primary Sequence of Cyclic Nucleotide Phosphodiesterase Isozymes and the Design of Selective Inhibitors," <i>TIPS Reviews</i> , <u>11</u> : 150-155 (April 1990)	
R6	Stoclet, "Cyclic Nucleotide Phosphodiesterases as the Therapeutic Targets in Cardiovascular Diseases," <i>Exp. Opin. Invest. Drugs</i> , <u>4</u> (11): 1081-1100 (1995)	

EXAMINER	DATE CONSIDERED
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	